Altimmune, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $<0.1 | $<0.1 | $0.4 | -$0.1 | $4.4 |
| Operating income | -$94.5 | -$103.2 | -$95.9 | -$87.7 | -$96.9 |
| Net income | -$88.1 | -$95.1 | -$88.4 | -$84.7 | -$97.1 |
| Balance Sheet | |||||
| Total debt | $35.0 | — | — | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$67.5 | — | -$75.9 | -$62.7 | -$90.4 |
Shares outstanding 194.5M · Free float 89.3%
Annual filing data through FY ended December 31, 2025; float as of September 27, 2026.